Side by Side
Compare
Read two to four stocks on the same scale — return, valuation and volatility in one table.
Selected1M Return
Partial Period · Jul 31, 2026 — Sep 4, 2026
Period Return
Each series is converted to a percentage of its own starting point, so all of them begin at zero. What is compared is the return over the period, not price levels.
| Metric | AKRO | MRNA | PFE |
|---|---|---|---|
| Return | |||
| Last Price | — | — | 28.52 |
| Daily Change | — | — | − 1.01% |
| Period ReturnPast Month | — | + 148.05% | + 14.01%Jul 31, 2026 — Sep 4, 2026 |
| Valuation | |||
| Market Cap | $4.50 B | $58.0 B | $163 B |
| P/E Ratio | — | — | — |
| Dividend Yield | — | — | — |
| Net MarginTrailing 12M | — | 141.4% | — |
| Risk | |||
| Beta | 0.90 | 1.22 | — |
| 52-Week Range | 41.77 — $54.83 | 22.28 — $176.66 | — |
| Company | |||
| Sector | — | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology | Pharmaceuticals |
Company
- AKROBiotechnology
- MRNAHealth Care · Biotechnology
- PFEHealth Care · Pharmaceuticals
Metrics could not be loaded for PFE: P/E, dividend, beta and the 52-week range stay empty in that column.
FinnhubUpdated 21:54
To Understand This